

## Use of alglucosidase alfa (Myozyme™) within NHS Wales

***Please disseminate the following information to the appropriate individuals within your organisation across NHS Wales.***

Dear Colleague

The First Minister has endorsed AWMSG's recommendation that the use of alglucosidase alfa (Myozyme™) be supported for use within NHS Wales.

### **AWMSG recommendation:**

***It was agreed (by majority)*** that the recommendation to the Minister for Health & Social Services with regard to alglucosidase alfa (Myozyme™) is that alglucosidase alfa (Myozyme™) should be endorsed within NHS Wales for the treatment of Pompe disease in accordance with the licensed indication but with the specific restriction.

That there is presently insufficient evidence of clinical effectiveness in late-onset disease and AWMSG does not endorse its use in this group of patients at this stage.

AWMSG endorsed the use of alglucosidase alfa (Myozyme™), but with the specific exclusion of alglucosidase alfa (Myozyme™) in Late-onset Pompe disease of the Adult Onset form (Adult Onset disease) because of insufficient evidence of clinical effectiveness. The Committee was however persuaded that alglucosidase alfa (Myozyme™) should be available for the treatment of Late Onset Pompe disease of the Juvenile Onset form (Juvenile Onset Disease).

AWMSG recommends that:

1. Patients receiving alglucosidase alfa (Myozyme™) will be entered into the Pompe registry.
2. Treatment will be administered under the supervision of a physician experienced in the management of Pompe disease or other neuromuscular disorders.
3. Treatment will be administered according to agreed guidelines at appropriate centres.
4. The AWMSG recommendation will be reviewed in light of further evidence becoming available.

If you wish to view the appraisal meeting documentation please click on the link below.  
[AWMSG meeting documents October 2006](#)

This information has been disseminated by the AWMSG Secretariat.

**Professor Philip A. Routledge**  
**Acting Chairman AWMSG**

**8<sup>th</sup> December 2006**

This communication has been sent to the following:

Welsh Assembly Government

**LOCAL HEALTH BOARDS**

Local Health Boards in Wales Secretariat  
LHB Chief Executives  
LHB Medical Directors  
LHB Finance Directors  
LHB Nurse Directors  
Heads of Medicines & Pharmacy Management

**TRUSTS**

Trust Medical Directors  
Trust Finance Directors  
Trust Chief Executives  
MI Pharmacists  
Chief Pharmacists in Wales

**NATIONAL PUBLIC HEALTH**

Consultants in Pharmaceutical Public Health  
Directors of Public Health

**COMMITTEES**

AWMSG Members  
AWMSG Deputies  
AWMSG Steering Committee  
AWPAG Members  
AWPAG Deputies  
NHS Industry Group Members  
NHS Industry Group Deputies  
WMP Members

M&TC Chairs & Secretaries